Skip to main content

Amneal debuts 2 generics

The company is offering Lyvispah, a baclofen oral granules specialty product, and bexarotene gel, 1%.

Amneal is unveiling two generic products.

The company is offering Lyvispah, a baclofen oral granules specialty product approved by the Food and Drug Administration for the treatment of spasticity related to multiple sclerosis and other spinal cord disorders.

Lyvispah is the generic to oral baclofen tablets that provides flexible, customized dosing with 5 mg, 10 mg and 20 mg single-dose packets of granules, the company said.

[Read More: FDA approves biosimilar Neupogen]

The rapidly dissolving flavored granules provide an alternative for patients with spasticity who also have difficulty swallowing pills. The product can be administered three ways: poured directly into the patient’s mouth with or without water, mixed with liquids or foods, or through an enteral feeding tube, Amneal noted.

“This is the first specialty product launch for the business since Rytary (carbidopa and levodopa) in 2015, and the first in a cadence of new branded launches planned over the next several years. The launch of Lyvispah is the next step in our strategy to expand our specialty business and drive accelerated growth” said Chirag and Chintu Patel, co-CEOs. “As we build our position in the neurology space, we see a clear need for more options to treat spasticity resulting from multiple sclerosis and other spinal cord disorders based on individual patient’s needs. We believe Lyvispah provides that option.”

In January, Amneal announced the acquisition of Saol Therapeutics’ baclofen franchise and the expansion of its neurology presence into spasticity with Lyvispah and Lioresal (baclofen), a baclofen product delivered through an implantable intrathecal pump for use in the management of severe spasticity of cerebral or spinal origin for the institutional market.

[Read More: Amneal receives FDA blessing for 4 generics]

Baclofen, a skeletal muscle relaxant, is well established for the treatment of spasticity and spinal cord injuries. It was first approved by the FDA in 1977. The FDA-approved labeling says that Lyvispah oral granules are indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus and muscular rigidity, and may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Lyvispah is not indicated in the treatment of skeletal muscle spasms resulting from rheumatic disorders.

Lyvispah will be available through both specialty and retail channels upon launch, with a full patient support program. The company has partnered with BlinkRx, a patient access company, to support patients on Lyvispah with such services as free home delivery, Amneal said.

Baclofen has a market value of $130 million for the 12 months ending March 2022, according to IQVIA.

[Read More: Overcoming obstacles: Despite challenges, generics companies optimistic for 2022]

amneal bexarotene

Amneal also is debuting bexarotene gel, 1%, which is the generic of Targretin.

Amneal’s product is sold in a carton containing one 60 gram aluminum tube. The gel is a clear, colorless gelled solution with a homogenous consistency.

Approved on April 27 of this year with CGT exclusivity by the FDA, the Amneal product is the first generic equivalent for Targretin currently on the market, according to Amneal. 

[Read More: Amneal receives FDA nod for generic Durezol]

Bexarotene gel, 1% has a market value of $21,804,343 for the 12 months ending April 30, according to IQVIA.

Amneal Bexarotene gel, 1% is available through wholesalers and distributors, as well as directly to the trade. The company said that it is now shipping the product.

This ad will auto-close in 10 seconds